Actively Recruiting
Effects of Omega-3 Polyunsaturated Fatty Acids on Blood Lipids, Inflammatory Factors, and Body Composition in Patients with Hyperlipidemia
Led by Peking Union Medical College Hospital · Updated on 2025-01-01
120
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research focuses on patients with hyperlipidemia, a condition characterized by elevated blood lipids. It aims to evaluate the effects of Omega-3 polyunsaturated fatty acids (PUFA) on blood lipids, inflammatory factors, and body composition. Participants will be randomly assigned to either an intervention group receiving Omega-3 PUFA or a control group receiving a placebo, with all participants receiving nutritional counseling for a low-fat diet. Participants in the intervention group will take 3.6 grams per day of fish oil containing Omega-3 PUFA (EPA+DHA), while the control group will receive a placebo made of palm oil that looks identical to the active treatment. The study is blinded and randomized, with pills distributed by an investigational pharmacist according to a randomization table. Lipid levels, inflammatory markers, body weight, and body composition will be assessed at the start, middle, and end of the study. Throughout the study, participants will have their triglycerides, cholesterol, LDL cholesterol, TNF-alpha, hsCRP, interleukin-6, body weight, and BMI measured at three months. Researchers will track these markers to understand changes during the study period. Nutritional counseling and education are provided to support adherence to a low-fat diet. The total length of participation is at least three months, including regular assessments and monitoring of health and treatment effects.
CONDITIONS
Official Title
Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years old and above
- Diagnosed with hyperlipidemia meeting clinical criteria: triglycerides ≥1.7 mmol/L, or total cholesterol ≥5.2 mmol/L, or LDL cholesterol ≥3.4 mmol/L
- Fully understand and voluntarily sign informed consent
- Able to eat orally
- Able to follow the research protocol and comply with doctor and researcher instructions
You will not qualify if you...
- Currently receiving lipid-lowering drugs
- Hyperlipidemia caused by secondary conditions such as nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, glycogen storage disease, myeloma, fat atrophy, acute porphyria, polycystic ovary syndrome, or use of certain medications causing secondary dyslipidemia
- Severe diseases including heart, liver, kidney dysfunction, recent acute myocardial infarction, stroke, intracerebral hemorrhage, acute COPD attack, respiratory failure within 3 months; recent surgery within 3 months; or deemed unsuitable by clinician
- Hemorrhagic disease or bleeding tendency
- History of allergy to omega-3 polyenoic acid preparations
- Pregnant or lactating women
- Poor compliance or inability to complete follow-up
- Serious abnormal metabolism or need for further intervention making continued participation unsuitable as assessed by physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospita
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
K
Kang Yu, master
F
Fang Wang, master
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here